Teva Ends Oncology, Women’s Health R&D Following Strategic Review
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will focus its R&D resources on central nervous system disorders and respiratory disease, but will end investment in women’s health and oncology.
You may also be interested in...
Teva Shoots For Top Three In Pain And Respiratory
Teva’s new management has homed in on pain and respiratory disease as two core therapeutic areas. During the firm’s second quarter earnings call, CEO Erez Vigodman gave a sneak peek at his comprehensive portfolio review.
Novartis Thinks It Can Do Better With GSK’s Oncologics Than GSK Did
Novartis stresses the blockbuster potential, in its hands, of three products – Votrient, Tafinlar and Mekinist – that it is acquiring from GSK as part of its narrowed focus on innovative pharmaceuticals, eye care and generics, and the divestment of vaccines, OTCs and animal health.
Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?
Wall Street is mixed on whether Teva’s newly approved three-times-weekly formulation will protect its MS blockbuster franchise.